author-photo

Vandana G. Abramson

Vanderbilt University
Vanderbilt University Medical Center

157

Papers

3605

Citations

Citation Trend

Filter By

Papers (157) Sort By

Journal Conference Others

Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (1)
Abstract PS12-20: A dose escalation study of the novel oral SERD-ZN-c5 in women with ER-positive, HER2-negative advanced/metastatic breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab.

2021 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (7)
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (1)
Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer

2021 International Journal of Molecular Sciences
Show All
- Source
- Cite
- Save
Citations (0)
565TiP A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A dose escalation study of the noveloral SERD-ZN-c5 in women with ER-positive, HER2-negative advanced/metastatic breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract OT-13-09: Translational breast cancer research consortium 044 trial: Randomized phase 2 study of pembrolizumab and carboplatin versus carboplatin alone for chest wall recurrence of breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)